Tyrosine kinase receptor--nuclear protooncogene interactions in breast cancer.

R. B. Dickson, D. S. Salomon, Marc E Lippman

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

In summary, evidence is beginning to accumulate in support of a major role for tyrosine kinase receptors (and their activating growth factors) and steroid hormones and their receptors in normal development and differentiation of the mammary gland. A point of intersection of their mechanisms of action in growth control appears to be the induction of nuclear protooncogenes such as c-myc. When c-myc is amplified, as it is in many breast cancers, EGF and FGF receptor tyrosine kinase action becomes transforming, not simply mitogenic. A source of the transforming factors could be either stromal or epithelial. This mechanism could function early in the progression of breast cancer. c-erbB-2 and EGF receptor overexpression and amplification, when they occur, appear to render tumors even more malignant and of especially poor prognosis. These mechanisms could function late in the progression of breast cancer. Transgenic mouse studies have begun to echo these themes. They have established that a growth factor (TGF-alpha) and its receptor (EGF receptor), which appear to be important in normal mouse and human proliferation and gland development, and a protooncogene (c-myc), commonly amplified and overexpressed in human and mouse breast cancer, can each contribute to mammary carcinogenesis. The mechanisms of the two are likely to be distinct. myc is likely to be acting as a tumor initiator in combination with normal proliferative factors, whereas TGF-alpha is likely to be acting as a hyperproliferative (promotional) factor in combination with a normal background of mutational events. The role of unmutated but amplified erbB-2 in the transgenic mouse is not yet known.

Original languageEnglish
Pages (from-to)249-273
Number of pages25
JournalCancer Treatment and Research
Volume61
StatePublished - Dec 1 1992
Externally publishedYes

Fingerprint

Receptor Protein-Tyrosine Kinases
Epidermal Growth Factor Receptor
Breast Neoplasms
Transgenic Mice
Intercellular Signaling Peptides and Proteins
Transforming Growth Factor alpha
Human Mammary Glands
Carcinogens
Protein-Tyrosine Kinases
Carcinogenesis
Breast
Steroids
Hormones
Growth
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dickson, R. B., Salomon, D. S., & Lippman, M. E. (1992). Tyrosine kinase receptor--nuclear protooncogene interactions in breast cancer. Cancer Treatment and Research, 61, 249-273.

Tyrosine kinase receptor--nuclear protooncogene interactions in breast cancer. / Dickson, R. B.; Salomon, D. S.; Lippman, Marc E.

In: Cancer Treatment and Research, Vol. 61, 01.12.1992, p. 249-273.

Research output: Contribution to journalArticle

Dickson, RB, Salomon, DS & Lippman, ME 1992, 'Tyrosine kinase receptor--nuclear protooncogene interactions in breast cancer.', Cancer Treatment and Research, vol. 61, pp. 249-273.
Dickson, R. B. ; Salomon, D. S. ; Lippman, Marc E. / Tyrosine kinase receptor--nuclear protooncogene interactions in breast cancer. In: Cancer Treatment and Research. 1992 ; Vol. 61. pp. 249-273.
@article{52b9a5c7b8d04c05bf033cb942ae1b27,
title = "Tyrosine kinase receptor--nuclear protooncogene interactions in breast cancer.",
abstract = "In summary, evidence is beginning to accumulate in support of a major role for tyrosine kinase receptors (and their activating growth factors) and steroid hormones and their receptors in normal development and differentiation of the mammary gland. A point of intersection of their mechanisms of action in growth control appears to be the induction of nuclear protooncogenes such as c-myc. When c-myc is amplified, as it is in many breast cancers, EGF and FGF receptor tyrosine kinase action becomes transforming, not simply mitogenic. A source of the transforming factors could be either stromal or epithelial. This mechanism could function early in the progression of breast cancer. c-erbB-2 and EGF receptor overexpression and amplification, when they occur, appear to render tumors even more malignant and of especially poor prognosis. These mechanisms could function late in the progression of breast cancer. Transgenic mouse studies have begun to echo these themes. They have established that a growth factor (TGF-alpha) and its receptor (EGF receptor), which appear to be important in normal mouse and human proliferation and gland development, and a protooncogene (c-myc), commonly amplified and overexpressed in human and mouse breast cancer, can each contribute to mammary carcinogenesis. The mechanisms of the two are likely to be distinct. myc is likely to be acting as a tumor initiator in combination with normal proliferative factors, whereas TGF-alpha is likely to be acting as a hyperproliferative (promotional) factor in combination with a normal background of mutational events. The role of unmutated but amplified erbB-2 in the transgenic mouse is not yet known.",
author = "Dickson, {R. B.} and Salomon, {D. S.} and Lippman, {Marc E}",
year = "1992",
month = "12",
day = "1",
language = "English",
volume = "61",
pages = "249--273",
journal = "Cancer Treatment and Research",
issn = "0927-3042",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Tyrosine kinase receptor--nuclear protooncogene interactions in breast cancer.

AU - Dickson, R. B.

AU - Salomon, D. S.

AU - Lippman, Marc E

PY - 1992/12/1

Y1 - 1992/12/1

N2 - In summary, evidence is beginning to accumulate in support of a major role for tyrosine kinase receptors (and their activating growth factors) and steroid hormones and their receptors in normal development and differentiation of the mammary gland. A point of intersection of their mechanisms of action in growth control appears to be the induction of nuclear protooncogenes such as c-myc. When c-myc is amplified, as it is in many breast cancers, EGF and FGF receptor tyrosine kinase action becomes transforming, not simply mitogenic. A source of the transforming factors could be either stromal or epithelial. This mechanism could function early in the progression of breast cancer. c-erbB-2 and EGF receptor overexpression and amplification, when they occur, appear to render tumors even more malignant and of especially poor prognosis. These mechanisms could function late in the progression of breast cancer. Transgenic mouse studies have begun to echo these themes. They have established that a growth factor (TGF-alpha) and its receptor (EGF receptor), which appear to be important in normal mouse and human proliferation and gland development, and a protooncogene (c-myc), commonly amplified and overexpressed in human and mouse breast cancer, can each contribute to mammary carcinogenesis. The mechanisms of the two are likely to be distinct. myc is likely to be acting as a tumor initiator in combination with normal proliferative factors, whereas TGF-alpha is likely to be acting as a hyperproliferative (promotional) factor in combination with a normal background of mutational events. The role of unmutated but amplified erbB-2 in the transgenic mouse is not yet known.

AB - In summary, evidence is beginning to accumulate in support of a major role for tyrosine kinase receptors (and their activating growth factors) and steroid hormones and their receptors in normal development and differentiation of the mammary gland. A point of intersection of their mechanisms of action in growth control appears to be the induction of nuclear protooncogenes such as c-myc. When c-myc is amplified, as it is in many breast cancers, EGF and FGF receptor tyrosine kinase action becomes transforming, not simply mitogenic. A source of the transforming factors could be either stromal or epithelial. This mechanism could function early in the progression of breast cancer. c-erbB-2 and EGF receptor overexpression and amplification, when they occur, appear to render tumors even more malignant and of especially poor prognosis. These mechanisms could function late in the progression of breast cancer. Transgenic mouse studies have begun to echo these themes. They have established that a growth factor (TGF-alpha) and its receptor (EGF receptor), which appear to be important in normal mouse and human proliferation and gland development, and a protooncogene (c-myc), commonly amplified and overexpressed in human and mouse breast cancer, can each contribute to mammary carcinogenesis. The mechanisms of the two are likely to be distinct. myc is likely to be acting as a tumor initiator in combination with normal proliferative factors, whereas TGF-alpha is likely to be acting as a hyperproliferative (promotional) factor in combination with a normal background of mutational events. The role of unmutated but amplified erbB-2 in the transgenic mouse is not yet known.

UR - http://www.scopus.com/inward/record.url?scp=0027017680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027017680&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 249

EP - 273

JO - Cancer Treatment and Research

JF - Cancer Treatment and Research

SN - 0927-3042

ER -